#Sustainability #South Korea #ESG Report #Samsung Biologics #Incheon

Samsung Biologics Unveils 2026 ESG Report

Samsung Biologics, a top contract development and manufacturing organization (CDMO), has recently published its annual ESG report for 2026, unveiling a range of advancements in sustainable operations and responsible growth strategies. This report underlines the company's enduring commitment to integrating sustainability into its core business practices while aligning with the evolving expectations of clients, stakeholders, and the broader bioscience industry.

Commitment to Sustainability

The latest ESG report illustrates Samsung Biologics' steadfast dedication to transparency and accountability. To enhance the effectiveness of its disclosures, the company has aligned its reporting framework with the European Sustainability Reporting Standards (ESRS). Additionally, it has published a comprehensive ESG Factbook that distills key sustainability data and performance metrics into a user-friendly format.

Over the reporting period, Samsung Biologics accelerated its environmental performance by increasing its transition to renewable energy, effectively managing greenhouse gas emissions, and improving carbon reporting accuracy. Notably, the company reported a remarkable increase in its renewable energy transition rate, reaching 39.8% under its RE100 roadmap. Furthermore, the transparency of Scope 3 greenhouse gas emissions reporting increased from 56.3% to 63.7%, allowing for greater visibility throughout its value chain.

The significant third-party validation of its product carbon footprint (PCF) methodology enhances the company’s communications regarding sustainability efforts. In recognition of its efforts, Samsung Biologics received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP), underscoring its ongoing environmental stewardship and resource management.

Social Initiatives and Stakeholder Engagement

On the social front, Samsung Biologics has concentrated on talent development and supply chain engagement. The company collaborates with premier educational institutions to implement career development programs aimed at nurturing future biotechnology leaders. Additionally, to empower its workforce, Samsung Biologics has made strides in fostering professional growth and leadership opportunities, particularly for women.

The expansion of supplier sustainability assessments has seen participation increase to 57.3%, reinforcing responsible sourcing practices and enhancing overall supply chain resilience.

Enhanced Governance Framework

In terms of governance, Samsung Biologics has bolstered its ethical risk management and oversight practices, ensuring a more diversified evaluation approach. This methodology enhances the objectivity and credibility of governance oversight, promoting effective decision-making and long-term value creation for the company.

Industry Collaboration for Greater Impact

Beyond internal efforts, Samsung Biologics actively engages with stakeholders across the healthcare landscape to support overarching sustainability goals. As a dedicated participant in the Sustainable Markets Initiative (SMI) Health Systems Task Force, the company plays a vital role in collaborative efforts aimed at cultivating more sustainable healthcare value chains. This involvement also includes supporting the industry’s transition to lower carbon output.

John Rim, President and CEO of Samsung Biologics, emphasized the fundamental role sustainability plays in the company’s operations and value creation: "Sustainability is an important part of how we operate and create long-term value. Through steady investments in environmental performance, robust governance, and industry-wide collaboration, we aim to contribute to the long-term resilience of the industry and the patients it serves."

The full ESG report is available here.

About Samsung Biologics

Samsung Biologics stands at the forefront of the biopharmaceutical contract development and manufacturing sector, offering integrated services from the late discovery phase to commercial production. With a formidable manufacturing capacity of 845,000 liters across its facilities in Korea and the United States, and plans for future expansion, Samsung Biologics is committed to delivering safe and high-quality biomedicines while making sustainable decisions that contribute to society and global health.

For further information on Samsung Biologics, visit their website.